$TLSI
TriSalus Life Sciences, Inc. Stock $tlsi

$tlsi Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000182666724000005 Filed on April 11, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$7.364M	$5.721M	$18.51M
YoY Change	59.67%
Cost Of Revenue	$912.0K	$582.0K	$2.605M
YoY Change	18.13%		15.37%
Gross Profit	$6.452M	$5.139M	$15.91M
YoY Change	68.02%		56.86%
Gross Profit Margin	87.62%	89.83%	85.93%
Selling, General & Admin	$9.960M	$11.62M	$40.55M
YoY Change	18.4%	756.9%	1376.48%
% of Gross Profit	154.37%	226.08%	254.91%
Research & Development	$4.666M	$7.639M	$29.51M
YoY Change	-32.0%		38.17%
% of Gross Profit	72.32%	148.65%	185.53%
Depreciation & Amortization	$194.0K	$202.0K	$702.0K
YoY Change	-41.92%		154.35%
% of Gross Profit	3.01%	3.93%	4.41%
Operating Expenses	$14.63M	$19.26M	$70.06M
YoY Change	-4.24%	1320.32%	2451.08%
Operating Profit	-$8.174M	-$14.12M	-$54.15M
YoY Change	471.61%		1871.87%
Interest Expense	$877.0K	$59.00K	-$3.938M
YoY Change	-124.55%	-96.38%	-230.45%
% of Operating Profit
Other Income/Expense, Net	-$44.00K	-$21.45M	-$941.0K
YoY Change	-109.21%	7983.9%	-110.63%
Pretax Income	-$4.325M	-$35.51M	-$59.03M
YoY Change	354.16%	-442291.78%	-1066.12%
Income Tax	$7.000K	$1.000K	$9.000K
% Of Pretax Income
Net Earnings	-$4.332M	-$36.31M	-$63.28M
YoY Change	335.36%	10475.23%	-1242.37%
Net Earnings / Revenue	-58.83%	-634.66%	-341.83%
Basic Earnings Per Share	-$0.21		-$6.73
Diluted Earnings Per Share	-$0.21	-$0.81	-$2.05
COMMON SHARES
Basic Shares Outstanding	26.76M shares	26.32M shares	9.396M shares
Diluted Shares Outstanding	23.90M shares		9.396M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.48M	$11.78M	$11.78M
YoY Change	322.16%	7569.31%	7569.31%
Cash & Equivalents	$16.48M	$11.78M	$11.78M
Short-Term Investments
Other Short-Term Assets	$3.311M	$5.972M	$5.972M
YoY Change	-31.86%	2794.39%	2794.39%
Inventory	$3.443M	$2.545M	$2.545M
Prepaid Expenses	$3.311M	$2.986M
Receivables	$4.706M	$3.554M	$3.554M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$27.94M	$20.86M	$20.86M
YoY Change	17205.86%	5696.74%	5696.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.830M	$3.270M	$3.270M
YoY Change	-42.94%	46.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$424.0K	$466.0K	$466.0K
YoY Change	15.53%	-97.65%	-97.65%
Total Long-Term Assets	$4.490M	$4.863M	$4.863M
YoY Change	-62.82%	-75.47%	-75.47%
TOTAL ASSETS
Total Short-Term Assets	$27.94M	$20.86M	$20.86M
Total Long-Term Assets	$4.490M	$4.863M	$4.863M
Total Assets	$32.43M	$25.73M	$25.73M
YoY Change	165.01%	27.43%	27.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.976M	$3.391M	$3.391M
YoY Change	-54.01%	135.01%	135.01%
Accrued Expenses	$9.407M	$10.88M	$10.80M
YoY Change	-0.87%	70.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$76.00K
YoY Change
Total Short-Term Liabilities	$12.00M	$14.69M	$14.69M
YoY Change	98.91%	487.01%	487.01%
LONG-TERM LIABILITIES
Long-Term Debt	$21.29M	$0.00	$88.00K
YoY Change		-100.0%	-93.44%
Other Long-Term Liabilities	$23.30M	$36.98M	$36.89M
YoY Change	1293.36%	276.87%	275.97%
Total Long-Term Liabilities	$21.29M	$36.98M	$36.98M
YoY Change	1173.09%	231.55%	231.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.00M	$14.69M	$14.69M
Total Long-Term Liabilities	$21.29M	$36.98M	$36.98M
Total Liabilities	$56.58M	$51.66M	$51.66M
YoY Change	269.51%	278.36%	278.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$265.9M	-$248.4M
YoY Change	1658.71%	1772.11%
Common Stock	$2.000K	$2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$24.15M	-$25.94M	-$25.94M
YoY Change
Total Liabilities & Shareholders Equity	$32.43M	$25.73M	$25.73M
YoY Change	165.01%	27.43%	27.43%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$4.332M	-$36.31M	-$63.28M
YoY Change	335.36%	10475.23%	-1242.37%
Depreciation, Depletion And Amortization	$194.0K	$202.0K	$702.0K
YoY Change	-41.92%		154.35%
Cash From Operating Activities	-$13.42M	-$8.849M	-$50.05M
YoY Change	-29.5%	599.14%	1728.47%
INVESTING ACTIVITIES
Capital Expenditures	$60.00K	$372.0K	$588.0K
YoY Change	57.89%		-10.23%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$328.0K	-$1.533M
YoY Change	-100.0%	-100.14%	-100.66%
Cash From Investing Activities	-$60.00K	-$700.0K	-$2.121M
YoY Change	-147.62%	-100.3%	-100.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$9.348M
YoY Change			-95.98%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	25.99M	43.00K	54.63M
YoY Change	93.79%	-100.02%	-123.7%
NET CHANGE
Cash From Operating Activities	-13.42M	-8.849M	-50.05M
Cash From Investing Activities	-60.00K	-700.0K	-2.121M
Cash From Financing Activities	25.99M	43.00K	54.63M
Net Change In Cash	12.51M	-9.506M	2.463M
YoY Change	-327.47%	17497.19%	-5304.88%
FREE CASH FLOW
Cash From Operating Activities	-$13.42M	-$8.849M	-$50.05M
Capital Expenditures	$60.00K	$372.0K	$588.0K
Free Cash Flow	-$13.48M	-$9.221M	-$50.63M
YoY Change	-29.33%		1392.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29510000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21358000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12738000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001826667
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	us-gaap	Derivative Loss Statement Of Income Or Comprehensive Income Extensible Enumeration DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#DerivativeGainLossOnDerivativeNet
CY2023	us-gaap	Derivative Gain Statement Of Income Or Comprehensive Income Extensible Enumeration DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#DerivativeGainLossOnDerivativeNet
CY2023	us-gaap	Fair Value Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
CY2023Q4	tlsi	Common Stock Share Price Market Price Number Of Consecutive Trading Days CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays	P3D
CY2023Q3	tlsi	Preferred Stock Number Of Trading Days Volume Weighted Average Price PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice	P10D
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.trisaluslifesciences.com/20231231#LeaseLiabilityCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.trisaluslifesciences.com/20231231#LeaseLiabilityCurrent
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.trisaluslifesciences.com/20231231#LeaseLiabilityNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.trisaluslifesciences.com/20231231#LeaseLiabilityNoncurrent
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39813
CY2023	dei	Entity Registrant Name EntityRegistrantName	TRISALUS LIFE SCIENCES, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-3009869
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	6272 W 91st Ave
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Westminster
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80031
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4015002	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	4015002	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	11645271	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26758295	shares
CY2023	dei	Auditor Firm AuditorFirmId	185
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	Denver, Colorado
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11777000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9414000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3554000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1557000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2545000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1471000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2986000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4772000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	20862000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	17214000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2091000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2231000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1179000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1381000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1127000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	802000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	466000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	367000	usd
CY2023Q4	us-gaap	Assets Assets	25725000	usd
CY2022Q4	us-gaap	Assets Assets	21995000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3391000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4947000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10556000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6377000	usd
CY2023Q4	tlsi	Lease Liability Current LeaseLiabilityCurrent	351000	usd
CY2022Q4	tlsi	Lease Liability Current LeaseLiabilityCurrent	370000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	389000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	142000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14687000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32357000	usd
CY2023Q4	tlsi	Lease Liability Noncurrent LeaseLiabilityNoncurrent	1244000	usd
CY2022Q4	tlsi	Lease Liability Noncurrent LeaseLiabilityNoncurrent	1593000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	18632000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	17100000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	369000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	51663000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	34319000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	164006000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	10.00
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30898162	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26413213	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	347926	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	347926	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10028000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186358000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-176330000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21995000	usd
CY2023	us-gaap	Gross Profit GrossProfit	15906000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	17034000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23512000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12483000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-54150000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-36439000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	431000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	180000	usd
CY2023	us-gaap	Interest Expense InterestExpense	16000	usd
CY2022	us-gaap	Interest Expense InterestExpense	1000	usd
CY2023	tlsi	Gain Loss On Equity Issuance GainLossOnEquityIssuance	-4353000	usd
CY2022	tlsi	Gain Loss On Equity Issuance GainLossOnEquityIssuance	-8312000	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-10855000	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2186000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-10293000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-379000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-420000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-59029000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-47178000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-59038000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-47187000	usd
CY2023	us-gaap	Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	2981000	usd
CY2022	us-gaap	Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	2829000	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1258000	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-63277000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50016000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.73
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-161.55
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-161.55
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9395748	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9395748	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	309609	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	309609	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-129605000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	94000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	368000	usd
CY2022	us-gaap	Preferred Stock Convertible Down Round Feature Increase Decrease In Equity Amount1 PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1	0	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-176330000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	180000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1402000	usd
CY2023	us-gaap	Preferred Stock Convertible Down Round Feature Increase Decrease In Equity Amount1 PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1	0	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	204236000	usd
CY2023	tlsi	Adjustments To Additional Paid In Capital Warrants Assumed In Reverse Recapitalization AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization	2568000	usd
CY2023	tlsi	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	957000	usd
CY2023	tlsi	Adjustments To Additional Paid In Capital Contingent Consideration Liability AdjustmentsToAdditionalPaidInCapitalContingentConsiderationLiability	28927000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	34150000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-59038000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-47187000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	702000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	398000	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-10855000	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2186000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-10293000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1402000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	368000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-44000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-310000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	190000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2023	tlsi	Gain Loss On Milestone Payment For Asset Acquisition GainLossOnMilestonePaymentForAssetAcquisition	-1000000	usd
CY2022	tlsi	Gain Loss On Milestone Payment For Asset Acquisition GainLossOnMilestonePaymentForAssetAcquisition	-1000000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1979000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	200000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1073000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	179000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1032000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2592000	usd
CY2023	tlsi	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	202000	usd
CY2022	tlsi	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	112000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-281000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-87000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2839000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5246000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50045000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32313000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	588000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	655000	usd
CY2023	tlsi	Payments For Assets Acquisition Milestone PaymentsForAssetsAcquisitionMilestone	1000000	usd
CY2022	tlsi	Payments For Assets Acquisition Milestone PaymentsForAssetsAcquisitionMilestone	1000000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	533000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	131000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2121000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1786000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	242000	usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	9189000	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	13499000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	9630000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2023	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	20000	usd
CY2022	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	usd
CY2023	tlsi	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	36854000	usd
CY2022	tlsi	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	0	usd
CY2023	tlsi	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	1116000	usd
CY2022	tlsi	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	0	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	87000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	131000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	179000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	94000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54629000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13462000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2463000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20637000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9664000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30301000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12127000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	14000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	19000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12000	usd
CY2023	tlsi	Class Of Warrant Or Right Transfer Of Warrant To Preferred Stock ClassOfWarrantOrRightTransferOfWarrantToPreferredStock	25409000	usd
CY2022	tlsi	Class Of Warrant Or Right Transfer Of Warrant To Preferred Stock ClassOfWarrantOrRightTransferOfWarrantToPreferredStock	0	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	Nature Of Business<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2023 (the "Closing Date"), TriSalus Life Sciences, Inc., a Delaware corporation (the “Company,” “TriSalus,” “we,” “us”), formerly known as MedTech Acquisition Corporation (“MTAC”), consummated the previously announced merger pursuant to the Agreement and Plan of Merger, dated as of November 11, 2022, as amended by that certain First Amendment to Agreement and Plan of Merger, dated as of April 4, 2023, the Second Amendment to Agreement and Plan of Merger, dated as of May 13, 2023, and the Third Amendment to Agreement and Plan of Merger, dated as of July 5, 2023 (as amended, the “Merger Agreement”), by and between MTAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of MTAC (“Merger Sub”) and TriSalus Operating Life Sciences, Inc. (formerly known as TriSalus Life Sciences, Inc.), a Delaware corporation (“Legacy TriSalus”), whereby Merger Sub merged with and into Legacy TriSalus with the separate corporate existence of Merger Sub ceasing (the “Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”) and TriSalus Life Sciences, Inc. becoming the surviving company. The closing of the Business Combination is herein referred to as “the Closing.” In connection with the consummation of the Merger, on August 10, 2023, Legacy TriSalus changed its name from TriSalus Life Sciences, Inc. to TriSalus Operating Life Sciences, Inc., and MTAC changed its name from MedTech Acquisition Corporation to TriSalus Life Sciences, Inc., the surviving company ("New TriSalus”). As further described in Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(3) Business Combination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Legacy TriSalus was deemed to be the accounting acquirer and predecessor company in the Business Combination. Thus, the prior periods presented in these consolidated financial statements are of Legacy TriSalus.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult to treat liver and pancreatic cancer. Our technology is utilized in the delivery of our therapeutics and administered by interventional radiologists. We are developing and marketing two product lines — Pressure Enabled Drug Delivery (“PEDD™) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. The combination of our PEDD technology with nelitolimod is focused on solving the two main barriers in the tumor micro environment that inhibits the success of immunotherapy. The first barrier (mechanical) is comprised of high intratumoral pressure within tumors that limits drug uptake and the second barrier (biological) is the reversal of intratumoral immunosuppression. Our PEDD with SmartValve™ is the only technology designed to work in synchrony with the cardiac cycle to open collapsed vessels in the tumor to enable deeper perfusion and improve therapeutic drug delivery in tumors with high intratumoral pressure. PEDD with SmartValve has been shown in prospective and retrospective clinical studies and in multiple pre-clinical models to improve therapy uptake and tumor response. nelitolimod has a dual mechanism of action in solid tumors which includes the alteration of the tumor microenvironment by reducing immunosuppressive myeloid derived suppressor cells while simultaneously activating immune response and recruiting T cells to the tumor, allowing checkpoint inhibitors to work more effectively.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TriNav™ is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. Current sales consist of the TriNav Infusion System, introduced in 2020, and a family of related guiding catheters. In 2020, we gained transitional pass-through payments (“TPT”) approval from the Centers for Medicare & Medicaid Services (“CMS”), which allows hospitals to cover the cost of using TriNav. The approval expired at the end of 2023. On June 1, 2023, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we applied for a new technology APC code with CMS. In December 2023, CMS granted a New Technology Healthcare Common Procedure Coding System ("HCPCS") code for procedures involving TriNav. This new code, HCPCS C9797, has been assigned to the Ambulatory Payment Classification ("APC") code 5194 - Level 4 Endovascular procedures. The new code became effective on January 1, 2024, and may be reported by hospital outpatient departments and ambulatory surgical centers.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the full potential of our technology can be realized through the combination of our drug delivery technology with immune-oncology drugs, so, in July 2020, we acquired our first immune-oncology drug, nelitolimod, and began clinical development of nelitolimod for treatment of liver and pancreatic cancers.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have funded operations to date principally with proceeds from the sale of preferred stock, from the issuance of debt and convertible debt, the exercise of warrants, and from proceeds received upon the closing of the Business Combination. Since inception of the Company in 2009 through December 31, 2023, we have issued for cash $164,364 of preferred stock, (of which $36,854 was raised at the closing of the Business Combination, including issuance of Series A convertible preferred stock), which, along with $560 of common stock and $57,466 of convertible notes and warrants, has funded the cumulative net losses of $248,377. During the year ended December 31, 2023, we raised a total of $9,189 in </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash through issuance of Series B-2 and B-3 preferred stock, $9,630 from the exercise of warrants, and $179 from the exercise of stock options. See note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(14) Convertible Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion of the convertible debt, warrants and the 2023 financing rounds.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had cash, cash equivalents and restricted cash of $12,127. The Company is still in its early stage, has a history of recurring operating losses, has yet to generate revenues sufficient to create positive cash flow and has accumulated deficit of $248,377 as of December 31, 2023. We are currently undergoing a strategic transformation from a company focused solely on the sale of our infusion systems to a therapeutic company whereby our medical devices will be marketed alongside the pharmaceutical drugs and other treatments that the devices deliver to patients. This transformation requires that we restructure our operating infrastructure, resulting in an increase in operating expenses — including the development of a candidate pharmaceutical — that, in the short term, will not be fully offset by increased revenues. Without additional financing and based on our sales, operations and research and development plans, our management estimates that our existing cash and cash equivalents will be insufficient to fund our projected liquidity requirements for the next 12 months.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements, Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period. In evaluating our ability to continue as a going concern, management projected our cash flow sources and needs and evaluated the conditions and events have raised substantial doubt about our ability to continue as a going concern within one year after the date that these consolidated financial statements were issued. Management’s plans to address the conditions and events have considered our current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of these consolidated financial statements in considering whether we have the ability to fund future operations and meet our obligations as they become due in the normal course of business.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to fund future operations and to continue the execution of our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through a combination of collaborations, strategic alliances and licensing arrangements, and issuance of additional equity and/or long-term debt. As described in note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(13) Standby Equity Purchase Agreement, w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e have the right but not the obligation to sell up to $30,000 of our Common Stock at our request under Standby Equity Purchase Agreement, subject to terms and conditions specified in the agreement. Outside of this agreement, there can be no assurance that we will be able to raise such additional financing or, if available, that such financing can be obtained on satisfactory terms. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring clinical trials and capital expenditures, and reducing other operating costs.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current operating plan, which is in part determined based on our most recent results and trends, along with the items noted above, causes substantial doubt to exist about our ability to continue as a going concern and management’s plans do not alleviate the existence of substantial doubt. Our financial statements have been prepared assuming we will continue as a going concern, which contemplates the continuity of normal business activities and realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various risks and uncertainties frequently encountered by companies in the early stages of growth, particularly companies in the rapidly evolving market for medical technology-based and pharmaceutical products and services. Such risks and uncertainties include, but are not limited to, a limited operating history, need for additional capital, a volatile business and technological environment, the process to test and obtain approval to market the candidate pharmaceutical, an evolving business model, and demand for our products. To address these risks, we must, among other things, gain access to capital in sufficient amounts and on acceptable terms, maintain and increase our customer base, implement and successfully execute our business strategy, develop the candidate pharmaceutical, continue to enhance our technology, provide superior customer service, and attract, retain, and motivate qualified personnel. There can be no guarantee that we will succeed in addressing such risks.</span></div>
CY2023	tlsi	Number Of Product Lines In Development NumberOfProductLinesInDevelopment	2	product_line
	tlsi	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	36854000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	560000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-248377000	usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	9189000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	179000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12127000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-248377000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.91pt">Concentrations of Credit Risk and Other Risks and Uncertainties</span><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash is deposited primarily with two financial institutions. At times, the deposits in these institutions may exceed the amount of insurance provided on such deposits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant risk on these balances.</span></div>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:8.01pt">Use of Estimates</span><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of warrant liabilities and tranche liabilities, the contingent earnout liability, certain of our clinical expense accruals, and the valuation allowance on deferred tax assets.</span></div>
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	2816224	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14266605	shares
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q4	tlsi	Standby Equity Purchase Agreement Term StandbyEquityPurchaseAgreementTerm	P24M
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	40150000	usd
CY2023Q3	tlsi	Reverse Recapitalization Net ReverseRecapitalizationNet	36854000	usd
CY2023Q3	tlsi	Reverse Recapitalization Transaction Costs Incurred ReverseRecapitalizationTransactionCostsIncurred	6069000	usd
CY2023Q3	tlsi	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	1742000	usd
CY2023Q3	tlsi	Reverse Recapitalization Transaction Costs Paid ReverseRecapitalizationTransactionCostsPaid	4327000	usd
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26316681	shares
CY2023	us-gaap	Advertising Expense AdvertisingExpense	1346000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	2201000	usd
CY2023	tlsi	Preferred Stock Offering Percent Of Outstanding Shares Ownership Percentage Shares Offered To PreferredStockOfferingPercentOfOutstandingSharesOwnershipPercentageSharesOfferedTo	0.992
CY2023Q3	tlsi	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.02471853	shares
CY2023Q3	tlsi	Stock Converted Reverse Recapitalization StockConvertedReverseRecapitalization	21999886	shares
CY2023Q3	tlsi	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.02471853	shares
CY2023Q3	tlsi	Proceeds From Reverse Recapitalization Transaction ProceedsFromReverseRecapitalizationTransaction	42854000	usd
CY2023Q3	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	2704000	usd
CY2023Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4015002	shares
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.00
CY2023Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	40150000	usd
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023Q3	tlsi	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P5Y
CY2023	tlsi	Preferred Stock Offering Percent Of Outstanding Shares Ownership Percentage Shares Offered To PreferredStockOfferingPercentOfOutstandingSharesOwnershipPercentageSharesOfferedTo	0.992
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14266605	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	28927000	usd
CY2023Q3	tlsi	Class Of Warrant Or Right Repurchase Program Authorized Amount ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount	4000000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	18632000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11777000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9414000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	350000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	250000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12127000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9664000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	350000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	607000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	753000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1938000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	718000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2545000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1471000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	117000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	43000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	5184000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	4656000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	3093000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	2425000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2091000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2231000	usd
CY2023	us-gaap	Depreciation Depreciation	684000	usd
CY2022	us-gaap	Depreciation Depreciation	276000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-44000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-310000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	122000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	190000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	88000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	88000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	88000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	88000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	88000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	687000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1127000	usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	usd
CY2023Q4	tlsi	Accrued Clinical Trial Liability Current AccruedClinicalTrialLiabilityCurrent	3115000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2790000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	3736000	usd
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	327000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	557000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	31000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10556000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6377000	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	28927000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	18632000	usd
CY2023	tlsi	Class Of Warrant Or Right Threshold Number Of Days For Warrants To Be Transferable ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable	P30D
CY2023Q3	tlsi	Class Of Warrant Or Right Repurchase Program Authorized Amount ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount	4000000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	305000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	9000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	9000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	9000	usd
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	9000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.034
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.020
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.220
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.190
CY2023	tlsi	Effective Income Tax Rate Reconciliation Disallowed Interest Expense On Convertible Debt Percent EffectiveIncomeTaxRateReconciliationDisallowedInterestExpenseOnConvertibleDebtPercent	0
CY2022	tlsi	Effective Income Tax Rate Reconciliation Disallowed Interest Expense On Convertible Debt Percent EffectiveIncomeTaxRateReconciliationDisallowedInterestExpenseOnConvertibleDebtPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.010
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.010
CY2023	tlsi	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	-0.034
CY2022	tlsi	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	-0.050
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	37322000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30421000	usd
CY2023Q4	tlsi	Deferred Tax Assets Fixed Assets And Intangibles DeferredTaxAssetsFixedAssetsAndIntangibles	2565000	usd
CY2022Q4	tlsi	Deferred Tax Assets Fixed Assets And Intangibles DeferredTaxAssetsFixedAssetsAndIntangibles	2371000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1115000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	815000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	222000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	76000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	37000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	35000	usd
CY2023Q4	tlsi	Deferred Tax Assets Right Of Use Assets DeferredTaxAssetsRightOfUseAssets	46000	usd
CY2022Q4	tlsi	Deferred Tax Assets Right Of Use Assets DeferredTaxAssetsRightOfUseAssets	52000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	10176000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4613000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	76000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	51788000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	38459000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	470000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	101000	usd
CY2023Q4	tlsi	Deferred Tax Assets Before Valuation Allowance DeferredTaxAssetsBeforeValuationAllowance	51318000	usd
CY2022Q4	tlsi	Deferred Tax Assets Before Valuation Allowance DeferredTaxAssetsBeforeValuationAllowance	38358000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	51318000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	38358000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13192000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8728000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	tlsi	Standby Equity Purchase Agreement Term StandbyEquityPurchaseAgreementTerm	P24M
CY2023Q4	tlsi	Purchase Agreement Ownership Limitation PurchaseAgreementOwnershipLimitation	0.0499
CY2023Q4	tlsi	Standby Equity Purchase Agreement Maximum Allowable Percentage Of Outstanding Common Stock StandbyEquityPurchaseAgreementMaximumAllowablePercentageOfOutstandingCommonStock	0.1999
CY2023	tlsi	Standby Equity Purchase Agreement Number Of Advances StandbyEquityPurchaseAgreementNumberOfAdvances	5	advance
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1258000	usd
CY2023Q3	tlsi	Preferred Stock Automatic Conversion Period PreferredStockAutomaticConversionPeriod	P4Y
CY2023Q3	tlsi	Preferred Stock Conversion Price Floor PreferredStockConversionPriceFloor	2.10
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	164006000	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	160507000	usd
CY2022	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	3499000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	164006000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	164006000	usd
CY2023	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	39968000	usd
CY2023	tlsi	Temporary Equity Value Conversion Of Convertible Securities TemporaryEquityValueConversionOfConvertibleSecurities	203974000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	9630000	usd
	tlsi	Class Of Warrant Or Right Transfer Of Warrant To Preferred Stock ClassOfWarrantOrRightTransferOfWarrantToPreferredStock	25409000	usd
CY2023	tlsi	Reverse Recapitalization Stock Value If Converted Amount ReverseRecapitalizationStockValueIfConvertedAmount	220000000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30898162	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	48081610	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	19194622	shares
CY2023	tlsi	Number Of Equity Incentive Plans NumberOfEquityIncentivePlans	2	plan
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7766000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21896348	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16879990	shares
CY2023	us-gaap	Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	2981000	usd
CY2023	tlsi	Income Loss From Preferred Stock Convertible Down Round Feature Per Basic Share IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare	0.32
CY2023Q4	tlsi	Lessee Number Of Operating Leases LesseeNumberOfOperatingLeases	4	lease
CY2023Q4	tlsi	Lessee Number Of Finance Leases LesseeNumberOfFinanceLeases	4	lease
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1179000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	233000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	275000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	76000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1156000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	88000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	473000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	443000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	13000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	16000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4000	usd
CY2023	tlsi	Finance Lease Cost FinanceLeaseCost	16000	usd
CY2022	tlsi	Finance Lease Cost FinanceLeaseCost	20000	usd
CY2023	us-gaap	Lease Cost LeaseCost	489000	usd
CY2022	us-gaap	Lease Cost LeaseCost	463000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	380000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	87000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	205000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	77000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	213000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	9000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	219000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	7000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	226000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	657000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1900000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	180000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	470000	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	16000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1431000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	164000	usd
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.081
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.081
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	580000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	431000	usd
CY2023	tlsi	Defined Contribution Plan Employer Matching Contribution Percent Of Employees Gross Pay Rate One DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayRateOne	0.03
CY2023	tlsi	Defined Contribution Plan Employer Matching Contribution Percent Of Employees Gross Pay Rate Two DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayRateTwo	0.035
CY2023	tlsi	Defined Contribution Plan Employer Matching Contribution Percent Of Employees Gross Pay Rate Three DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayRateThree	0.04
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04

Files In Submission

Name	View Source	Status
0001826667-24-000005-index-headers.html	Edgar Link	pending
0001826667-24-000005-index.html	Edgar Link	pending
0001826667-24-000005.txt	Edgar Link	pending
0001826667-24-000005-xbrl.zip	Edgar Link	pending
ex1019amendmenttomarshakar.htm	Edgar Link	pending
ex231auditorconsentapril11.htm	Edgar Link	pending
ex311ceo302certification1.htm	Edgar Link	pending
ex312cfo302certification1.htm	Edgar Link	pending
ex321ceo906certification1.htm	Edgar Link	pending
ex322cfo906certification1.htm	Edgar Link	pending
ex41trisalus-descriptionof.htm	Edgar Link	pending
ex971trisalus-clawbackpoli.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_1.jpg	Edgar Link	pending
image_2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
picture1a.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tlsi-20231231.htm	Edgar Link	pending
tlsi-20231231.xsd	Edgar Link	pending
tlsi-20231231_g1.jpg	Edgar Link	pending
tlsi-20231231_g2.jpg	Edgar Link	pending
tlsi-20231231_def.xml	Edgar Link	unprocessable
tlsi-20231231_lab.xml	Edgar Link	unprocessable
tlsi-20231231_pre.xml	Edgar Link	unprocessable
tlsi-20231231_htm.xml	Edgar Link	completed
tlsi-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TLSI
TriSalus Life Sciences, Inc. Stock $tlsi

2024 Q2 Form 10-K Financial Statement

#000182666724000005 Filed on April 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TLSI TriSalus Life Sciences, Inc. Stock $tlsi

2024 Q2 Form 10-K Financial Statement

#000182666724000005 Filed on April 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TLSI
TriSalus Life Sciences, Inc. Stock $tlsi